Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hypereosinophilic Syndrome 1Chondrosarcoma 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × nilotinib × Clear all
NCT01222143 2015-06-22

Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia

University Health Network, Toronto

Phase 1/2 Terminated
12 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00762632 2012-08-08

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Technical University of Munich

Phase 1/2 Completed
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡